Skip to main content

SYSTEMATIC REVIEW article

Front. Pharmacol.
Sec. Drugs Outcomes Research and Policies
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1429709

Efficacy and safety of lebrikizumab for the treatment of moderate-to-severe atopic dermatitis: A systematic review and meta-analysis

Provisionally accepted
Jinger Lin Jinger Lin 1,2*Min Luo Min Luo 1,2Qianwei Zhuo Qianwei Zhuo 1,2Nuo Chen Nuo Chen 1,2Haosong Zhang Haosong Zhang 1,2Yue Han Yue Han 1,2
  • 1 Fujian Medical University, Fuzhou, China
  • 2 Department of Dermatology, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, China

The final, formatted version of the article will be published soon.

    Background: Lebrikizumab, an IL-13 immunomodulator, has shown recommendable effectiveness and safety in clinical studies for the treatment of moderate-to-severe atopic dermatitis (AD) in adolescents and adults.Objective: To explore the efficacy and safety of lebrikizumab in the treatment of moderate-to-severe AD by meta-analysis.: PubMed, Embase, Web of Science, Medline and ClinicalTrials.gov databases were searched through August 8, 2023. Randomized clinical trials of treatment with lebrikizumab for moderate-to-severe AD were included screening titles, abstracts and papers. Results: A total of five studies involving 1551 patients with AD were identified. Pooled analysis revealed significant improvements in Eczema Area and Severity Index score (SMD = -0.527; 95% CI = [-0.617,-0.436]), Investigator's Global Assessment score (RR = 2.122; 95% CI = [1.803,2.496]), Body Surface Area score (SMD = -0.608; 95%CI = [-1.099,-0.118]), SCORing Atopic Dermatitis score (SMD = -0.441; 95%CI= [-0.633,-0.250]), Pruritus Numeric Rating Scale score, Patient-oriented Eczema Measure scores, Sleep-loss Likert scale score and Dermatology Life Quality Index scores showed similar results. Adverse events (RR = 0.984;95% CI=[0.907,1.068]) for lebrikizumab showed no statistically significant difference to placebo and were the same as serious adverse events (RR = 0.748;95% CI=[0.410,1.364]).This meta-analysis showed that lebrikizumab has higher efficacy and safety in the treatment of moderate-to-severe AD and the 250 mg Q2w dosage regimen appears to be more advantageous.

    Keywords: Lebrikizumab, Meta-analysis, atopic dermatitis, efficacy, Safety

    Received: 08 May 2024; Accepted: 16 Oct 2024.

    Copyright: © 2024 Lin, Luo, Zhuo, Chen, Zhang and Han. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Jinger Lin, Fujian Medical University, Fuzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.